ASX - By Stock
|
NEU |
Re:
Ann: Phase 2 trial shows significant improvements in Pitt Hopkins
|
|
yankyfly
|
160 |
78K |
40 |
28/05/24 |
28/05/24 |
ASX - By Stock
|
160
|
78K
|
40
|
|
ASX - By Stock
|
QPM |
Re:
Associated News
|
|
yankyfly
|
3.2K |
936K |
1 |
28/01/24 |
28/01/24 |
ASX - By Stock
|
3.2K
|
936K
|
1
|
|
ASX - By Stock
|
QPM |
Re:
Associated News
|
|
yankyfly
|
3.2K |
936K |
2 |
21/01/24 |
21/01/24 |
ASX - By Stock
|
3.2K
|
936K
|
2
|
|
ASX - By Stock
|
QPM |
Re:
Associated News
|
|
yankyfly
|
3.2K |
936K |
12 |
19/01/24 |
19/01/24 |
ASX - By Stock
|
3.2K
|
936K
|
12
|
|
ASX - By Stock
|
OPT |
Re:
Ann: Opthea to Receive US$35M Commitment and Additional US$50M
|
|
yankyfly
|
32 |
13K |
0 |
02/01/24 |
02/01/24 |
ASX - By Stock
|
32
|
13K
|
0
|
|
ASX - By Stock
|
OPT |
Re:
Ann: Change of Director's Interest Notice - MB
|
|
yankyfly
|
1 |
623 |
3 |
21/12/23 |
21/12/23 |
ASX - By Stock
|
1
|
623
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Ann: P2 trial shows significant improvements in Phelan-McDermid
|
|
yankyfly
|
210 |
88K |
37 |
18/12/23 |
18/12/23 |
ASX - By Stock
|
210
|
88K
|
37
|
|
ASX - By Stock
|
IXC |
Re:
IXC Charting Thread
|
|
yankyfly
|
523 |
94K |
5 |
27/06/23 |
27/06/23 |
ASX - By Stock
|
523
|
94K
|
5
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex Granted European Orphan Drug Designation for TBI
|
|
yankyfly
|
74 |
16K |
2 |
27/06/23 |
27/06/23 |
ASX - By Stock
|
74
|
16K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
yankyfly
|
10K |
4.7M |
4 |
23/05/23 |
23/05/23 |
ASX - By Stock
|
10K
|
4.7M
|
4
|
|
ASX - By Stock
|
OPT |
Re:
Ann: Half Year Accounts
|
|
yankyfly
|
88 |
37K |
3 |
15/05/23 |
15/05/23 |
ASX - By Stock
|
88
|
37K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
yankyfly
|
241 |
47K |
4 |
22/02/23 |
22/02/23 |
ASX - By Stock
|
241
|
47K
|
4
|
|
ASX - By Stock
|
OPT |
Re:
Ann: Opthea secures up to US$170m in non-dilutive financing
|
|
yankyfly
|
35 |
20K |
1 |
24/01/23 |
24/01/23 |
ASX - By Stock
|
35
|
20K
|
1
|
|
ASX - By Stock
|
OPT |
Re:
Ann: Opthea secures up to US$170m in non-dilutive financing
|
|
yankyfly
|
35 |
20K |
2 |
16/01/23 |
16/01/23 |
ASX - By Stock
|
35
|
20K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
yankyfly
|
1.0K |
533K |
2 |
10/11/22 |
10/11/22 |
ASX - By Stock
|
1.0K
|
533K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Ann: FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial
|
|
yankyfly
|
30 |
15K |
55 |
30/03/22 |
30/03/22 |
ASX - By Stock
|
30
|
15K
|
55
|
|